Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avidity Biosciences Inc (NQ: RNA )

46.13 +1.01 (+2.24%)
Streaming Delayed Price Updated: 12:47 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Avidity Biosciences Inc

< Previous 1 2 3 4 5 Next >
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
Via Benzinga
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while utilities lagged. 
Via Benzinga
Topics ETFs
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
(RNA) - Analyzing Avidity Biosciences's Short Interest
Via Benzinga
Chart Of The Day: Avidity Biosciences - Something's Up?
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. 
Via Talk Markets
A Glimpse Into The Expert Outlook On Avidity Biosciences Through 6 Analysts
Via Benzinga
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, CleanSpark, Enovix Corp, Axcelis Tech, Intellia Therapeutics, Korn Ferry. 
Via Benzinga
Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday
Via Benzinga
Crude Oil Moves Higher; Vera Bradley Shares Slide
Via Benzinga
Exposures Fossil Fuels
Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Navigating 7 Analyst Ratings For Avidity Biosciences
Via Benzinga
Where Avidity Biosciences Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Jumps 300 Points; Oracle Shares Spike Higher
Via Benzinga
Why Avidity Biosciences Shares Are Trading Higher Wednesday
The 39 patient trial was in relation to treating facioscapulohumeral muscular dystrophy (FSHD) with delpacibart braxlosiran. 
Via Benzinga
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
A Closer Look at 5 Analyst Recommendations For Avidity Biosciences
Via Benzinga
The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A High Point
The company is working on a treatment for a rare form of muscular dystrophy. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
2 Potentially High-Reward Growth Stocks to Buy Right Now
These two biotechnology stocks could be gearing up for a run. 
Via The Motley Fool
Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound
Discover three top Nasdaq stocks to buy. Learn about these investment opportunities and why they’re worth your attention. 
Via InvestorPlace
RNA Stock Earnings: Avidity Biosciences Misses EPS, Beats Revenue for Q1 2024
RNA stock results show that Avidity Biosciences missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
Via Benzinga
Topics ETFs
This Demand Zone In S&P 500 Needs To Hold
Find out the demand zone that the S&P 500 needs to hold to avoid a meaningful pullback. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
Cantor Fitzgerald initiates coverage on Avidity Biosciences highlighting a robust pipeline led by del-desiran, a promising treatment for Myotonic dystrophy type 1. With strong management, proven... 
Via Benzinga
American Airlines To Rally Around 42%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Avidity Biosciences Says Lead Program Shows Reversal Of Disease Progression In Neuromuscular Disease
New AOC 1001 data from Avidity Biosciences show reversal of disease progression in DM1 patients, using key endpoints in Phase 3 HARBOR trial. 
Via Benzinga
Top 2% Biotech Avidity Collapses Despite 'Positive' Results In Treating Muscular Dystrophy
The company is working on a treatment for myotonic dystrophy type 1, a form of muscular dystrophy. 
Via Investor's Business Daily
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its... 
Via Benzinga
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.